My Profile

Search abstracts

Lewis Sheiner

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

København, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

   Paris, France

Billy Amzal - Frédéric Bois
Bayesian Optimal Design for the Study of Butadiene Toxicokinetics
Kim Emil Andersen and Malene Højbjerre
A Bayesian Approach to Bergman's Minimal Model
Susanne Bøttcher and Claus Dethlefsen
Bayesian Networks used in PK/PD modelling
Celine Brochot, William Couet, Andrew Gelman, Frederic Yves Bois
Assessing the Additivity of the Effects of Drugs in Mixtures
Jian-Feng Lu and René Bruno
Assessment of the Predictive Performance of a New Population Pharmacokinetic Model For Trastuzumab (Herceptin) and Simulation of Trastuzumab Steady-State Exposure During Long-Term Weekly Dosing.
Chanu Pascal, Tranchand Brigitte, Robert Jacques
Population pharmacokinetics of epirubicin and its main metabolite epirubicinol using NONMEM
Xuejun Chen, Suresh Mallikaarjun, Zhao Wang, Steven L. Bramer
Population PK Modeling of drugs exhibiting less than proportional increases in pharmacokinetics relative to increasing doses
L.Claret(1), P.Macheras(2), N.Simon(3), A.Iliadis(4)
The Use Of A Stochastic Model For Data Exhibiting Heterogeneous Pharmacokinetics
Eric Masson, 1, Eliane Fuseau, 2, Valérie Cosson, 2
Efficiency of Using Population Pharmacokinetics to Demonstrate Bioequivalence with Sparse Sampling in Cancer Patients- A Trial Simulation with Etoposide
C. Csajka(1), C. Marzolini(1), K. Fattinger(2), L.A. Décosterd(1), J. Fellay(3), A. Telenti(3), J. Biollaz(1), T. Buclin(1)
Population Pharmacokinetics and Effects of Efavirenz in HIV Patients
L. Del Frari, F. Bouzom, B. Walther and R.Jochemsen
Pharmacokinetic Mixed Effects Modelling of S16257 After Oral Administration in the Beagle Dog; Combined Analysis
Oscar Della Pasqua(1) and Eliane Fuseau(2)
Optimising Design In Paediatric Regulatory Studies
Stephen Duffull and Bruce Green
Prospective assessment of a D-optimal design for a population pharmacokinetic study of enoxaparin
J.B. Fau * & C. Dubruc *, F. Mentré **.
Population PK/PD modelling of a new MAO-B inhibitor in young and elderly healthy volunteers.
Freidig A, Onderwater R, Bogaards J, Bouzom F and Jochemsen R.
Development of a PBPK model for drug-drug interaction of orally delivered drugs using in-vitro data
Jan Freijer, Bart Ploeger, Joost DeJongh & Meindert Danhof
Extrapolation of pharmacokinetics and toxicity from pre-clinical data to humans
M.J. García1, D. Santos Buelga1,D. Aumente2, P. Gomez2 ,JC.Lukas1
Population pharmacokinetics of long-term methotrexate in children with lymphoblastic leukemia
D. Santos Buelga1, M.J. García1, MJ Otero2, A. Martin Suarez1, A. Dominguez-Gil2, JC.Lukas1
Phenytoin covariate models for Michaelis-Menten pharmacokinetics in adult epileptic patients
Marie Gårdmark
Regulatory aspects of population pharmacokinetic drug interaction studies
S. Gisbert, I. Gueorguieva, G. Graham, L. Aarons
Incorporating Uncertainty and Variability in the Physiological Parameters of a PBPK Model
Sophie Glatt1, Olivier Petricoul1, Ciara Rossier2, Quyen T.X Nguyen2, Alain Munafo2, Timothy Goggin2, Mauro Buraglio2, and Eliane Fuseau1
Pooled PK analysis of Interferon-beta-1a (Rebif), data obtained in healthy subjects and in patients.
Bruce Green and Stephen Duffull
Population pharmacokinetics and pharmacodynamics of enoxaparin in obese patients
Andreas V. Groth, Mikael S. Thomsen, Morten Colding-Jørgensen & Erik Mosekilde
Discussion of criteria for evaluating the quality of glucose clamp studies
I. Gueorguieva, I. Nestorov, M. Rowland
Reducing PBPK Models Using Global Sensitivity Analysis and Benefit/Cost Criterion
Nick Holford, Jianguo Li, Lisa Benincosa, Mattias Birath
Population Disease Progress Models for the Time Course of HAMD Score in Depressed Patients Receiving Placebo in Anti-Depressant Clinical Trials
F.Hourcade-Potelleret *, C. Laveille *, M.Tod ** and R. Jochemsen *
Mixture models : simulation and estimation with NONMEM
Ziad Hussein (1), Maria Pitsiu (1), Oneeb Majid (1), L. Aarons (2), A. Stockis (3) and M. de Longueville (3)
Retrospective Population Pharmacokinetics Of Cetirizine In Infants And Children
P.Baille-Albert (1), O.Petricoul (1), E.Fuseau (1), A.Iliadis (2)
Information indexes for exploratory data analysis in population pharmacokinetics
Christoffer W. Thornøe, Judith L. Jacobsen and Henrik Madsen
Grey-box Modelling of Insulin Clamp Study
Siv Jönsson and Mats O. Karlsson
Estimating Bias In Parameters For Some NONMEM Models For Ordered Categorical Data
Howard Lee, Hui C. Kimko, Mark Rogge, Diane Wang, Ivan Nestorov and Carl C. Peck
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
In-Sun Nam, Leon Aarons
The propagation of information in PK modelling: The use of IV information to support the analysis of PK data
Christian Laveille, PharmD (1), Lewis Sheiner, MD (2), Vincent Duval, PharmD (1), Guillemette Resplandy, PhD (1), and Roeline Jochemsen, PhD (1)
Simulations using a mechanistic DDI model: individual risk assessment.
R. H. Leary(1), R. Jelliffe(2), A. Schumitzky(2), and M. Van Guilder(2)
A Unified Parametric/Nonparametric Approach to PK/PD Population Modeling
A. Diot(1,2), C. Laveille(2), N. Frey(2), R. Jochemsen(2) & A. Mallet(1)
Gauss Hermite Quadrature in Population Parameters Estimation. Application to the Detection of Subpopulations
Lars Lindbom, Mats O. Karlsson, E. Niclas Jonsson
Symmetry and coverage of confidence intervals for a population PK model.
Mick Looby
Assessing the robustness of competing dose regimens to incomplete compliance
D. Martin , N. Frey , C. Laveille , H. Merdjan and R. Jochemsen
Pharmacokinetic mixed effects modelling of a new compound in rat - Combined analysis.
Merle Y.(1), Treluyer JM* (2), Tonnelier S (2), Rey E (2), Pons G (2).
Nonparametric Population Analysis Of Amikacin Pharmacokinetic Data In A Pediatric Population.
Sandrine MICALLEF, Thomas J. SMITH, Frédéric Y. BOIS
Modelling of intra-individual and inter-individual variability in 1,3-butadiene metabolism
Elena Mishina and Mehul Mehta
Assessment of the Contribution of Components in a Combination Drug Product Using Population PK Modeling
Hussain Mulla, Fazal Nabi, Sanjiv Nichani, Richard K Firmin, Graham Lawson, David R Upton
Population Pharmacokinetics of Theophylline during Paediatric Extracorporeal Membrane Oxygenation (ECMO)
L. Nguyen (1), S. Retout (2), F. Mentré (2), P. Variol (1) and C. Puozzo (1)
Population pharmacokinetics of vinflunine from phase I data and evaluation of population sampling designs for further clinical development
Perdaems Lambert N.(1), Bouzom F.(1), Freidig A.(2), Solbes Marchetti M.N.(1), Jochemsen R.(3), and Walther B.(1)
The Use Of Physiologically Based Pharmacokinetic (PBPK) Model In Drug Development
Juan Jose Perez Ruixo(1); Vladimir Piotrovsky(1); Kenneth H. Cowan(2); Louis Weiner (3); Cornelis J.A. Punt (4); Martine Piccart (5).
Population Pharmacokinetic Analysis of Zarnestra Using Data From Phase I Clinical Trials
Jose Pinheiro
Transformations and Variance Functions in Nonlinear Mixed-Effects Models
Vladimir Piotrovsky
Drug Efficacy Analysis as an Exercise in Dynamic (Indirect-Response) Population PK-PD Modeling
Sylvie Retout, France Mentré
Optimisation Of Individual And Population Pharmacokinetic Designs Using S-Plus
Jakob Ribbing and E. Niclas Jonsson
The Effect of Collinearity on the Selection of Covariates in Population Pharmacokinetic Analysis
Rizo-Manika M, Saivin S, Georges B, Conil JM, Lavit M, Houin G
Validation Of An Amikacin Population Pharmacokinetics Model To Be Used In Intensive Care Unit
Georges B., Saivin S., Archambaud M., Conil JM., Decun JF., Cougot P., Virenque C., Houin G.
Cefepime Monitoring in ICU Patients Using a Population Pharmacokinetic Approach
Lewis Sheiner, MD.
Dealing With Missing Data Through Random Effects Models
Eric Snoeck
Model Evaluation
Michel Tod
Handling Concentrations Below Quantification Limit in Population
Brigitte Tranchand1, Silvy Laporte2
Design and practical problems in population PK studies in the elderly
Iñaki F. Trocóniz*, Ilonka Zsolt**, María J. Garrido*, Marta Valle**, and Manel J. Barbanoj**
Dealing with Autoinhibition of Drug Clearance in Early Clinical Product Development
Valle M, Riba J, Yritia M, Barbanoj MJ.
Pharmacokinetics of the three main alkaloids present in the South American psychoactive beverage Ayahuasca after oral administration to healthy volunteers
Vermeulen, An and Piotrovsky, Vladimir
Modelling of the effect of carbamazepine on the pharmacokinetics of risperidone in psychotic patients of different phenotypes
Ulrika Wählby(1), Alison H. Thomson(2), Peter A. Milligan(3) and Mats O. Karlsson(1)
Handling of time-varying covariates in population model building.
Xiaofeng Wang and Siu-Kei Tin
Population pharmacokinetics model validation using Kinetica
Charles Warlow
Sub-group Nonsense. Problems In Interpreting And Considering Covariates In Evaluation
G.Würthwein1, T.Klingebiel2, S.Krümpelmann3, M.Metz4, K.Schwenker4, C.Lanvers1, J. Boos1
Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens
A.A. Yao(a), J.T. Slattery(b,c), G.B. McDonald(c), and P. Vicini(a)
Population pharmacokinetics of cyclophosphamide and its metabolites in hematopoietic stem-cell transplantation patients
Stefano Zamuner, Roberto Gomeni, Alan Bye
Estimate the time varying brain receptor occupancy in PET imaging
Liping Zhang
Simultaneous vs. Sequential Estimation in PK/PD Data Analysis